NCT00736034

The Efficacy of Phosphatidylserine-Omega3 in Elderly Subjects With Memory Impairment

A Single-Center, Open-Label Study to Assess the Efficacy of SharpPS™-Gold in Elderly Subjects With Memory Impairment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Enzymotec · Industry
• Sex: All
• Age: 65 Years – 90 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this trial is to assess the ability of Phosphatidylserine-Omega3 to improve cognitive performance in elderly subjects with memory impairment. This study is a single-center, open-label 15 weeks duration trial to assess efficacy of Phosphatidylserine-Omega3 in elderly subjects with memory impairment.

Conditions

• Memory Impairment

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Phosphatidylserine-Omega3 (SharpPS™-Gold)	Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-03-01
• Completion: 2009-04-01
• First posted: 2008-08-15
• Last updated: 2010-03-30
• Results posted: 2010-03-24

Locations

1 site across 1 country: Israel